Drug Trial Radar · NCT07908329
Intradermal Influenza Vaccination
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
139
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chan Zuckerberg Initiative; Silicon Valley Community Foundation; Yale Development Award
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after vaccination. The primary objective is to identify baseline correlates of immune response in the skin and peripheral blood to the seasonal influenza vaccine. The investigators secondary goals are to describe the inflammatory response in the skin over time.
Conditions
- Vaccine Reaction
Interventions
MicronJetDevice
MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
Fluzone® QuadrivalentBiological
Intradermal injections of 0.3mL
Fluzone® QuadrivalentBiological
Intramuscular injection of 0.3mL
Fluzone® High Dose QuadrivalentBiological
For participants \>65 years old
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in antibody titer concentration to vaccination-BloodTime frame: Day 0 and Day 28
- Change in antibody titer concentration to vaccination-SkinTime frame: Day 0 and Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Church Street Research Unit
New Haven, Connecticut · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.